Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Sandoz Group Ag (0SAN) Share Price

Price 54.23213 on 20-11-2025 at 19:15:01
Change 0.00 0%
Buy 0.00
Sell 0.00
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 6,500.00 at 53.34
Day's Volume: 22,039
Last Close: 54.23213
Open: 0.00
ISIN: CH1243598427
Day's Range 0.00 - 0.00
52wk Range: 30.61 - 55.21657
Market Capitalisation: -
VWAP: 53.80629
Shares in Issue: 430.70m

Sector: Medicine and Biotech

Sandoz Group Ag (0SAN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 6,500 53.34 OTC Trade
 18:03:48 - 20-Nov-25
Unknown* 136 54.54031 OTC Trade
 17:38:14 - 20-Nov-25
Unknown* 1 55.21552 OTC Trade
 17:38:14 - 20-Nov-25
Unknown* 178 54.23213 SI Trade
Negotiated Trade
 17:32:17 - 20-Nov-25
Unknown* 25 53.3292 OTC Trade
 17:23:59 - 20-Nov-25
Unknown* 150 53.41734 OTC Trade
 17:17:54 - 20-Nov-25
Unknown* 4,689 53.99204 OTC Trade
 17:13:15 - 20-Nov-25
Unknown* 124 53.39291 SI Trade
Negotiated Trade
 17:08:14 - 20-Nov-25
Unknown* 691 53.39291 SI Trade
Negotiated Trade
 17:08:14 - 20-Nov-25
Unknown* 464 53.70734 OTC Trade
 17:06:13 - 20-Nov-25
See more Sandoz Group Ag trades

Sandoz Group Ag (0SAN) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Nov 2025 (Thu) 54.23213 54.23213 54.23213 54.23213 22,039
19th Nov 2025 (Wed) 53.94864 53.94864 53.94864 53.94864 76,551
18th Nov 2025 (Tue) 54.01004 54.01004 54.01004 54.01004 52,507
17th Nov 2025 (Mon) 54.96517 54.96517 54.96517 54.96517 72,202
14th Nov 2025 (Fri) 54.42514 54.42514 54.42514 54.42514 47,073
13th Nov 2025 (Thu) 55.18063 55.18063 55.18063 55.18063 98,446
12th Nov 2025 (Wed) 55.21657 55.21657 55.21657 55.21657 142,833
11th Nov 2025 (Tue) 54.49367 54.49367 54.49367 54.49367 327,947
10th Nov 2025 (Mon) 53.72342 53.72342 53.72342 53.72342 34,284
7th Nov 2025 (Fri) 52.88 52.88 52.88 52.88 138,354
6th Nov 2025 (Thu) 54.24 54.24 54.24 54.24 137,984
5th Nov 2025 (Wed) 54.28234 54.28234 54.28234 54.28234 63,424
4th Nov 2025 (Tue) 54.56369 54.56369 54.56369 54.56369 38,456
3rd Nov 2025 (Mon) 55.15845 55.15845 55.15845 55.15845 138,925
31st Oct 2025 (Fri) 53.5171 53.5171 53.5171 53.5171 251,109
30th Oct 2025 (Thu) 51.26918 51.26918 51.26918 51.26918 130,346
29th Oct 2025 (Wed) 50.68 50.68 50.68 50.68 122,353
28th Oct 2025 (Tue) 49.77268 49.77268 49.77268 49.77268 120,915
27th Oct 2025 (Mon) 49.79 49.79 49.79 49.79 21,382
24th Oct 2025 (Fri) 49.55 49.55 49.55 49.55 61,532
23rd Oct 2025 (Thu) 48.5913 48.5913 48.5913 48.5913 91,122
22nd Oct 2025 (Wed) 48.5612 48.5612 48.5612 48.5612 44,419
21st Oct 2025 (Tue) 48.64333 48.64333 48.64333 48.64333 34,820
20th Oct 2025 (Mon) 48.9262 48.9262 48.9262 48.9262 61,921
See more Sandoz Group Ag price history

Sandoz Group Ag (0SAN) Regulatory News

Date Source Headline
12th Aug 2025 6:00 am GNW Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
7th Aug 2025 6:00 am GNW Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
30th Jul 2025 6:15 am GNW Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
1st Jul 2025 1:56 pm GNW Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
2nd Jun 2025 6:00 am GNW Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
21st May 2025 4:30 pm GNW Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
30th Apr 2025 6:00 am GNW Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
29th Apr 2025 4:00 pm GNW Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
15th Apr 2025 12:50 pm GNW Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
14th Apr 2025 3:00 pm GNW [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
See more Sandoz Group Ag regulatory news
FTSE 100 Latest
Value9,527.65
Change20.24

Login to your account

Forgot Password?

Not Registered